Attenuation of GVHD for allo-bone marrow transplantation recipient by fasL-fas pathway in an H-2 haplotype disparate mouse combination

Summary In order to explore a new special and effective way to prevent, graft versus, host disease (GVHD) after allogenic bone marrow transplantation (alle-BMT), the stem cell antigen-1 (Sea-1) carly hematopoietic cells (EHC) from BALB/c mouse (H-2 d ) were introduced with exogenous mouse Fas ligand (mFasL) cDNA gene by the retrevirus-mediated gene transfer and expanded for one week, and then they were co-cultured with the spleen mononuclear cells (SMNC) from BAC mouse (H-2 d, h ) as one way mixed lymphocyte reaction (OWMLR). The cytotoxicity of treated BAC mouse SMNC against Na 2 51 CrO 4 labeling SMNC from BALB/c mouse was observed. The bone marrow mononuclear cells (BMMNC) from BAC mouse treated by the above methods were transplanted into lethally-irradiated congenic BALB/c mice to observe the occurrence of GVHD. The results showed that the SMNC from BAC mouse after OWMLR with exogenous mFasL cDNA gene-transduced hematopoietic cells (HC) from BALB/c mouse in a ratio of 1 to 5 exhibited an obvious inhibition of the cytotoxicity against the BALB/c mouse spleen cells at different effector/target ratios as compared to the control group ( P <0.01). The grade I GVHD or no GVHD and the 80% survival rate at day 60 post-BMT were observed in the BALB/c mouse receiving BAC mouse BMMNC treated with similar way, while the grade II–III GVHD and the 20% survival rate were noted in the control group ( P <0.01). It is suggested that the attenuation of GVHD in allo-BMT recipient could be successfully achieved through FasL-Fas pathway in an H-2 haplotype disparate mouse combination.